FSD Pharma has dosed the first cohort of patients in its Phase I clinical trial evaluating Lucid-MS for the treatment of multiple sclerosis (MS). “Our clinical development team and international advisory committee are delighted at the progress of this milestone and completing dosing the first cohort,” said Dr Lakshmi Kotra, CEO of Lucid Psycheceuticals. “The […]
